- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02855892
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
A Randomized, Placebo-controlled, Single-blind, Parallel Design, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be randomized equally between the four arms.
- Control group (placebo, two-week interval): 38 subjects
- Study group 1 (GV1001 0.4 mg, intradermal administration, two-week interval): 38 subjects
- Study group 2 (GV1001 0.56 mg, intradermal administration, two-week interval): 38 subjects
- Study group 3 (GV1001 0.56 mg, intradermal administration, four-week interval): 38 subjects
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of
- Inje University Busan Paik Hospital
-
Daegu, Korea, Republic of
- Keimyung University Dongsan Medical Center
-
Seoul, Korea, Republic of
- Eulji General Hospital
-
Seoul, Korea, Republic of
- Chung-ang University Hospital
-
Seoul, Korea, Republic of
- Severance Hospital
-
-
Gyeonggi-do
-
Guri-si, Gyeonggi-do, Korea, Republic of
- Hanyang University Guri Hospital
-
Seongnam-si, Gyeonggi-do, Korea, Republic of
- Seoul National University Bundang Hospital
-
-
Gyeongsangbuk-do
-
Gyeongju, Gyeongsangbuk-do, Korea, Republic of
- Dongguk university gyeongju hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
[Inclusion Criteria]
All of the following criteria should be satisfied to be enrolled in this clinical trial.
- A male at 50 years of age and older
A patient who satisfies the following clinical signs and symptoms of benign prostatic hyperplasia
① A patient with a volume of prostate gland (TRUS) > 30 cc
② A patient with moderate to severe lower urinary tract symptoms with IPSS ≥ 13
③ A patient with 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume was at least 125 mL
- A patient with PSA level < 10 ng/mL (however, if 4 ng/mL < PSA < 10 ng/mL, a person with a biopsy result, confirming that he does not have prostate cancer)
- A patient with residual urine volume ≤ 200 mL
- A patient with intention of not using drugs which may affect benign prostatic hyperplasia (5-alpha reductase inhibitors, drugs similar to LHRH, alpha blockers, alpha-beta blockers, anticholinergics, antidiuretic hormones, diuretics, PDE-5 inhibitors, beta-3 adrenoceptor antagonists, etc.), drugs affecting immune system (steroids, immunosuppressants), or health functional foods which may affect a prostate gland (saw palmetto, etc.) during the clinical trial period
- A patient has to consent not to participate in other clinical trials as a subject during this clinical trial period.
- Before enrollment to the study, a patient has to consent to avoid pregnancy by using condoms for 90 days after the end of study participation period and treatment. (However, this is not applied if the patient had vasectomy.) Also, a partner of the patient has to consent to avoid pregnancy by using contraceptive devices or oral contraceptives during the patient's participation in clinical trial and for 90 days after the end of treatment, except if the partner reaches menopause or is surgically sterilized. (Consent should be obtained before visit 4, when necessary.)
[Exclusion Criteria]
If any one of the following is applied, a patient cannot be enrolled in this clinical trial.
- A patient who has hypersensitivity reactions to ingredients of this drug.
- A patient who received 5-alpha reductase inhibitors other than a drug used in this clinical trial before randomization (within six months)
- A patient who received drugs similar to LHRH other than a drug used in this clinical trial
- A patient who has received an unapproved study drug in the past or the study drug for this clinical trial (One exception: a patient can be enrolled when the drug is considered by an investigator not to affect prostate and urinary function, and the patient is not participating in other ongoing clinical trial.)
- If diagnosed with prostate cancer in the past or at present
- A patient who was considered by an investigator to have an influence to an evaluation on urine flow symptoms due to other previous or current diseases besides benign prostatic hyperplasia (e.g., neurogenic bladder, bladder neck contracture, urethral stricture, bladder cancer, malignant tumor in lower urinary tract, etc.)
- A patient who had surgeries or radiation therapies for prostate gland, bladder or pelvis, or who had invasive treatments for benign prostatic hyperplasia
- A patient who has severe medical condition which may be cause problem to conduct the clinical trial (e.g., chronic heart failure (CHF), difficult-to-control diabetes (HbA1c > 7%), mental disorder, drug, or alcohol abuse, etc.)
- A patient with moderate to severe liver hypofunction and severe kidney hypofunction (less than 30 mL/min of creatinine clearance)
- A patient who receives drugs affecting immune system (e.g., immunosuppressives, steroids for systemic action, etc.)
- Any other patients who are considered to be ineligible for this study by an investigator
[Inclusion Criteria for Randomization]
A patient who satisfies the following clinical signs and symptoms of benign prostatic hyperplasia
① A patient with a volume of prostate gland (TRUS) > 30 cc *
② A patient with moderate to severe lower urinary tract symptoms with IPSS ≥ 13
③ A patient with 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume was at least 125 mL
- A patient with residual urine volume ≤ 200 mL
- A partner of the patient has to consent to avoid pregnancy by using contraceptive devices or oral contraceptives during the patient's participation in clinical trial and for 90 days after the end of treatment, except if the partner reaches menopause or is surgically sterilized.
(* In case that additional TRUS examination has been performed after screening, a decision should be made based on the latest result.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Control Group
- Placebo, two-week interval, intradermal administration
|
Other Names:
|
EXPERIMENTAL: Study Group 1
- GV1001 0.4 mg, two-week interval, intradermal administration
|
Other Names:
|
EXPERIMENTAL: Study Group 2
- GV1001 0.56 mg, two-week interval, intradermal administration
|
Other Names:
|
EXPERIMENTAL: Study Group 3
- GV1001 0.56 mg, four-week interval, intradermal administration : Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.) |
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of doses of GV1001 by comparing the level of change in IPSS scores in three study groups to a control group.
Time Frame: at Week 0, 4, 8, 12, 13, and 16
|
IPSS questionnaire: 7-item questionnaire that measures urinary symptoms, but with an additional, independent eighth question on quality of life.
It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score.
The first 7 items has a 6-point response scale (0=none/never to 5=almost always/5 or more times) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35).
The last item assesses quality of life reported as a Quality of Life assessment index.
|
at Week 0, 4, 8, 12, 13, and 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in volume of prostate gland (TRUS) compared to the baseline
Time Frame: at screening and Week 16
|
The amount of change from Transrectal Ultrasonography(TRUS) compared to the baseline
|
at screening and Week 16
|
Change in maximum flow rate (Qmax) compared to the baseline
Time Frame: at Week 0, 4, 8, 12, 13, and 16
|
The amount of change from Maximum(peak) Urinary Flow Rate compared to the baseline
|
at Week 0, 4, 8, 12, 13, and 16
|
Change in International Index of Erectile Function (IIEF) compared to the baseline
Time Frame: at Week 0, 4, 8, 12, 13, and 16
|
IIEF questionnaire: 15-item, 5 domain scale collected by subject interview, relating to the subjects' experience of erectile function (and other sexual parameters) over the previous 4 weeks.
|
at Week 0, 4, 8, 12, 13, and 16
|
Change in prostate-specific antigen (PSA) compared to the baseline
Time Frame: at Week 0, 13, and 16
|
The amount of change from Prostate-specific Antigen (PSA) compared to the baseline
|
at Week 0, 13, and 16
|
Change in residual urine volume compared to the baseline
Time Frame: at Week 0, 4, 8, 12, 13, and 16
|
The amount of change from Residual Urine Volume compared to the baseline
|
at Week 0, 4, 8, 12, 13, and 16
|
Change in hormones (testosterone, DHT) compared to the baseline
Time Frame: at Week 0, 4, 8, 12, 13, and 16
|
The amount of change from Hormones (Testosterone, DHT) compared to the baseline
|
at Week 0, 4, 8, 12, 13, and 16
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KG 3/2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia (BPH)
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Medi-Tate Ltd.CompletedBenign Prostatic Hyperplasia (BPH)Spain, Belgium, Italy, Switzerland, United Kingdom
-
University of Kansas Medical CenterEnrolling by invitationBenign Prostatic Hyperplasia | BPHUnited States
-
Brooklyn Urology Research GroupAmerican Medical Systems; Richard Wolf Medical Instruments Corporation (RWMIC)CompletedBenign Prostatic Hyperplasia (BPH)United States
-
Daniel Stephan EngelerCompletedBenign Prostatic Hyperplasia (BPH)Switzerland
-
HistoSonics, Inc.WithdrawnBenign Prostatic Hyperplasia (BPH)
-
Watson PharmaceuticalsCompletedBenign Prostatic Hyperplasia (BPH)United States
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Lawson Health Research InstituteGyrus ACMI, Inc.CompletedBenign Prostatic Hyperplasia | BPHCanada
-
Dr. med. Gautier MüllhauptRecruitingBenign Prostatic Hyperplasia (BPH)Switzerland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States